Trial · NCT02434523

Trial of the Treatment of Chronic Laryngitis With Amitryptiline

NCT02434523, Phase 2, Phase 3, Terminated, Boston Medical Center; results first posted 2016-11-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of the Treatment of Chronic Laryngitis With Amitryptiline. Trials, record NCT02434523. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02434523

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of the Treatment of Chronic Laryngitis With Amitryptiline
NCT number: NCT02434523
Status: Terminated
Phases: Phase 2, Phase 3
Enrollment: 30 participants, actual
Lead sponsor: Boston Medical Center
Conditions: Laryngeal Diseases, Chronic Laryngeal Neuropathy
Interventions: Amitriptyline, Placebo
First posted: 2015-05-05
Last updated: 2016-11-30
Results first posted: 2016-11-30
Limitations and caveats: Early termination leading to small numbers of subjects analyzed

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Reflux Symptom Index	8 weeks	Reflux symptom index change in score after treatment Range possible: 0 to 45 Higher values indicate worse symptoms / outcomes
Secondary	Voice Handicap Index	8 weeks	Voice handicap index change in score after treatment Possible range: 0 to 40 Higher values indicate worse symptoms / outcomes
Secondary	Side Effects	8 weeks	number of patients with side effects, type of side effects
Secondary	Lost to Follow up	8 weeks

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Reflux Symptom Index	8 weeks	Patients who completed treatment and post-treatment questionnaire	units on a scale	MEAN
SECONDARY	Voice Handicap Index	8 weeks		units on a scale	MEAN
SECONDARY	Side Effects	8 weeks		participants	NUMBER
SECONDARY	Lost to Follow up	8 weeks	number of subjects in each arm who were lost to follow up	participants	NUMBER

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Reflux Symptom Index	Amitriptyline		-2.7	Standard Deviation 7.1	units on a scale
Reflux Symptom Index	Placebo		0.3	Standard Deviation 12.0	units on a scale
Voice Handicap Index	Amitriptyline		3.7	Standard Deviation 6.1	units on a scale
Voice Handicap Index	Placebo		0	Standard Deviation 4.3	units on a scale
Side Effects	Amitriptyline	Dizziness	4		participants
Side Effects	Placebo	Dizziness	2		participants
Side Effects	Amitriptyline	Fatigue	3		participants
Side Effects	Placebo	Fatigue	1		participants
Side Effects	Amitriptyline	Dry mouth	1		participants
Side Effects	Placebo	Dry mouth	2		participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Amitriptyline	15
Overall Study	STARTED	Placebo	15
Overall Study	COMPLETED	Amitriptyline	10
Overall Study	COMPLETED	Placebo	9
Overall Study	NOT COMPLETED	Amitriptyline	5
Overall Study	NOT COMPLETED	Placebo	6

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Adverse Effect	Nervous system disorders	Amitriptyline	6	15	15
other	Adverse Effect	Nervous system disorders	Placebo	2	15	15

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Amitriptyline
Total, all-cause mortality	Placebo
Total, other adverse events	Amitriptyline	6	15
Total, other adverse events	Placebo	2	15
Total, serious adverse events	Amitriptyline	0	15
Total, serious adverse events	Placebo	0	15

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Amitriptyline vs Placebo: Lost to Follow up	Trial comparisons
Amitriptyline vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02434523

GET https://conductscience.org/api/trials/v1/NCT02434523/registered

API reference For AI assistants